Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents - PubMed (original) (raw)
Affiliations
- PMID: 9236857
Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents
D K Monteith et al. Anticancer Drug Des. 1997 Jul.
Abstract
Treatment of rodents with phosphorothioate oligodeoxynucleotides induces a form of immune stimulation characterized by splenomegaly, lymphoid hyperplasia, hypergammaglobulinemia and mixed mononuclear cellular infiltrates in numerous tissues. Immune stimulation was evaluated in mice with in vivo and in vitro studies using a review of historical data and specific in vivo and in vitro studies. All phosphorothioate oligodeoxynucleotides evaluated induced splenomegaly and B-lymphocyte proliferation. Splenomegaly and B-lymphocyte proliferation increased with dose or concentration of oligodeoxynucleotide. Splenomegaly appeared to occur, at least in part, as a result of stimulation of B-lymphocyte proliferation. There were differences with respect to degree or potency of immune stimulation by different oligodeoxynucleotides. The rank order potencies for B-lymphocyte proliferation in vitro and splenomegaly correlated well for the oligodeoxynucleotides tested. Particular oligodeoxynucleotide sequence motifs or palindromes have been demonstrated to affect in vitro cell proliferation. Inclusion of a 5'-AACGTT-3' palindrome in a phosphorothioate oligodeoxynucleotide sequence significantly enhanced the potency. While inclusion of this palindrome or a CpG motif alone may contribute to the immune stimulation, these palindromes and motifs were clearly not the sole factor required for immune stimulation. Several phosphorothioate oligodeoxynucleotides that did not contain a CpG motif still induced immune stimulation in mice. The immune stimulation induced by phosphorothioate oligodeoxynucleotides was an effect of this class of compounds to which rodents are acutely sensitive.
Similar articles
- Stimulation of thymocyte proliferation by phosphorothioate DNA oligonucleotides.
Mannon RB, Nataraj C, Pisetsky DS. Mannon RB, et al. Cell Immunol. 2000 Apr 10;201(1):14-21. doi: 10.1006/cimm.2000.1635. Cell Immunol. 2000. PMID: 10805969 - Phosphorothioate oligodeoxyribonucleotides induce in vitro proliferation of chicken B-cells.
Wattrang E. Wattrang E. Vet Immunol Immunopathol. 2009 Oct 15;131(3-4):218-28. doi: 10.1016/j.vetimm.2009.04.013. Epub 2009 Apr 23. Vet Immunol Immunopathol. 2009. PMID: 19447503 - Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.
Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. Henry S, et al. J Pharmacol Exp Ther. 2000 Feb;292(2):468-79. J Pharmacol Exp Ther. 2000. PMID: 10640282 - Adjuvant activity of CpG oligodeoxynucleotides.
Klinman DM. Klinman DM. Int Rev Immunol. 2006 May-Aug;25(3-4):135-54. doi: 10.1080/08830180600743057. Int Rev Immunol. 2006. PMID: 16818369 Review. - The response of human B lymphocytes to oligodeoxynucleotides.
Liang H, Lipsky PE. Liang H, et al. Springer Semin Immunopathol. 2000;22(1-2):63-75. doi: 10.1007/s002810000017. Springer Semin Immunopathol. 2000. PMID: 10944801 Review. No abstract available.
Cited by
- Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics.
Zhao N, Ho JSY, Meng F, Zheng S, Kurland AP, Tian L, Rea-Moreno M, Song X, Seo JS, Kaniskan HÜ, Te Velthuis AJW, Tortorella D, Chen YW, Johnson JR, Jin J, Marazzi I. Zhao N, et al. Cell Host Microbe. 2023 Jul 12;31(7):1154-1169.e10. doi: 10.1016/j.chom.2023.05.030. Epub 2023 Jun 5. Cell Host Microbe. 2023. PMID: 37339625 Free PMC article. - Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides.
Goyenvalle A, Jimenez-Mallebrera C, van Roon W, Sewing S, Krieg AM, Arechavala-Gomeza V, Andersson P. Goyenvalle A, et al. Nucleic Acid Ther. 2023 Jan;33(1):1-16. doi: 10.1089/nat.2022.0061. Epub 2022 Dec 28. Nucleic Acid Ther. 2023. PMID: 36579950 Free PMC article. Review. - Delivery of oligonucleotide-based therapeutics: challenges and opportunities.
Hammond SM, Aartsma-Rus A, Alves S, Borgos SE, Buijsen RAM, Collin RWJ, Covello G, Denti MA, Desviat LR, Echevarría L, Foged C, Gaina G, Garanto A, Goyenvalle AT, Guzowska M, Holodnuka I, Jones DR, Krause S, Lehto T, Montolio M, Van Roon-Mom W, Arechavala-Gomeza V. Hammond SM, et al. EMBO Mol Med. 2021 Apr 9;13(4):e13243. doi: 10.15252/emmm.202013243. Epub 2021 Apr 6. EMBO Mol Med. 2021. PMID: 33821570 Free PMC article. Review. - Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.
Dobrovolskaia MA, Bathe M. Dobrovolskaia MA, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jan;13(1):e1657. doi: 10.1002/wnan.1657. Epub 2020 Jul 15. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021. PMID: 32672007 Free PMC article. Review. - Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-_O_-Methoxyethyl Antisense Oligonucleotide.
Pirie E, Cauntay P, Fu W, Ray S, Pan C, Lusis AJ, Hsiao J, Burel SA, Narayanan P, Crooke RM, Lee RG. Pirie E, et al. Nucleic Acid Ther. 2019 Oct;29(5):266-277. doi: 10.1089/nat.2019.0797. Epub 2019 Aug 1. Nucleic Acid Ther. 2019. PMID: 31368839 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources